Form 4: Harmony Biosciences Executive Sells Shares Under 10b5-1 Trading Plan

Jeffrey Dierks, Chief Commercial Officer of Harmony Biosciences Holdings, Inc., sold shares of common stock on October 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jeffrey Dierks, the Chief Commercial Officer of Harmony Biosciences Holdings, Inc., reported the sale of common stock on October 3, 2024.
• The sales were executed under a Rule 10b5-1 trading plan.
• A total of 36,357 shares were sold in multiple transactions.
• The weighted average price for the first set of transactions was $35.0453, with prices ranging from $34.58 to $35.57.
• The weighted average price for the second set of transactions was $35.6191, with prices ranging from $35.59 to $35.69.
• Following the reported transactions, the number of shares beneficially owned by Dierks is 0.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. The sentiment is neutral as it simply reports the sale of shares by an executive under a pre-arranged trading plan.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies and are often conducted under pre-arranged trading plans like Rule 10b5-1 to avoid accusations of insider trading. The sale itself doesn't necessarily indicate a negative outlook for the company.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, potentially causing a slight decrease in stock price due to increased supply, but the impact is likely to be minimal given the pre-planned nature of the sale.

Key Dates